The page is the record's research on the issuer — no analyst, no rating, no view. # OKYO Pharma Ltd (NASDAQ: OKYO) — research page As of 2026-11-08 · us-cm-kg · record version 1 ## Identity and listing OKYO Pharma Ltd is listed on NASDAQ under the ticker OKYO. Its ISIN is USG6724L1165. Its LEI is not on the record, because no GLEIF record carries the exact legal name in jurisdiction US. Its security type is recorded as non-operating entity type (other). Its segment is not on the record. Its sector is 2836 Biological Products, (No Diagnostic Substances). Its jurisdiction is not on the record. Its status is listed, not halted. ## The disclosure read The record holds 88 filings in the twelve months from 2025-11-08 to 2026-11-08, across 47 filing days. The filings comprise 28 directors' dealings, 4 prospectuses, 11 regulatory filings and 45 results. The median gap between filing days is 4.0 days. The latest filing is a results filing dated 2026-11-05, 3 days before the record date of 2026-11-08. The NASDAQ median cadence gap is 6.0 days across 4,359 issuers, and the NASDAQ median filings count is 52, with a median latency of 5.0 days. The sector median cadence gap is 5.5 days across 176 issuers, the sector median filings count is 65.5, and the sector median latency is 4.0 days. ## Auditor The auditor of record is not on the record, because the latest annual report cover carries no dei:AuditorName tag. Its location is not on the record. The record holds no auditor changes. ## Events and halts The record holds no listing, delisting or name change lines. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The issuer is listed and not halted. ## Orderability The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04. ## Coverage Six research houses are named on the issuer's investor-relations page: H.C Wainwright & CO, Lucid, Piper Sandler, B Riley, Goldman Research Company and Goldman Research. ## Open research Six openly published research notes are on the record. Piper Sandler & Co. published notes dated 2026-08-01, 2026-07-01 and 2026-02-19. H.C. Wainwright & Co. published a note dated 2026-01-29. B. Riley Securities published a note dated 2025-12-08. Lucid Capital Markets published a note dated 2025-07-31. ## Licensed Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded. ## As-of depth The vintage is sealed. The sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The earliest sealed date of the market is 2021-01-04. The live record began on 2026-09-12. ## Sources 14 source pages are named on this page; every value above carries its own source page and read date in the numbers. - https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange) - https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin) - https://data.sec.gov/submissions/CIK0001849296.json (identity.name) - https://mcp.us-cm-kg.ai/events/NASDAQ/OKYO (the disclosure lines) - https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag) - https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter) - https://okyopharma.com/investors/analyst-coverage/ (coverage) - https://okyopharma.com/wp-content/uploads/2026/08/Piper-Note-August-2026.pdf (open research) - https://okyopharma.com/wp-content/uploads/2026/07/Piper-July-2026-Update.pdf (open research) - https://okyopharma.com/wp-content/uploads/2026/02/OKYO-Piper-Report-Feb-26.pdf (open research) - https://okyopharma.com/wp-content/uploads/2026/01/OKYO-HCW-FDA-Endorses-Planned-Phase-2b_3-Trial-in-Neuropathic-Corneal-Jan-26.pdf (open research) - https://okyopharma.com/wp-content/uploads/2025/12/OKYO-B-RIley-Initiation-PT-5.pdf (open research) - https://okyopharma.com/wp-content/uploads/2025/07/OKYO-Initiation-Report-by-Lucid-7-31-25.pdf (open research) - https://mcp.us-cm-kg.ai/record/NASDAQ/OKYO (the record) --- Allooloo Technologies Corp. · https://getresearch.ai/us/NASDAQ/OKYO · public-record only · the same page signed and receipted: get_research at https://mcp.getresearch.ai/mcp